Pipeline intelligence

Drug pipeline news

FDA decisions, trial results, new studies and deals for the drugs we track, taken directly from company press releases: those filed with the U.S. Securities and Exchange Commission and those issued on PR Newswire. Releases since Jun 23, 2026, retrieved Nov 20, 2026.

Search and filter disclosures

73 of 73 disclosures

  1. Pipeline updateCompany-reportedNov 18, 2026

    Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer Global Registration-Enabling Study to Evaluate...

    Ivonescimab Versus Durvalumab as Consolidation Therapy Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer (NSCLC).

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Other events
  2. RegulatoryCompany-reportedNov 16, 2026

    Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Complete Response Letter Received from FDA for BLA

    Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for ivonescimab in combination with platinum-containing chemotherapy for the treatment of patients with locally...

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Other events
  3. Quarterly reportCompany-reportedNov 12, 2026

    Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results

    The $11.2 million decrease is mainly due to the zerlasiran Phase 3 readiness being completed in 2025 as well as reduced personnel costs. • G&A Expenses: General and administrative (G&A) expenses were $4.9 million for the three months ended September 30, 2026, compared to $5.8 million for the three months ended...

    Source
    SEC Form 8-K · Financial results
  4. Quarterly reportCompany-reportedNov 4, 2026

    Financial report for the period 1 January 2026 to 30 September 2026

    Pipeline progress • Within obesity, CagriSema (1.0/1.0 mg) delivered encouraging weight loss of 21% at week 68 in the REDEFINE 9 trial. • Also in obesity, the AMAZE 9 phase 3 trial with oral zenagamtide has been initiated in September. • Within diabetes, CagriSema (1.0/1.0 mg) achieved superior weight loss of 12.4%...

  5. Quarterly reportCompany-reportedNov 4, 2026

    Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and...

    The company will continue to provide more details in the coming months with respect to additional Phase III studies evaluating ivonescimab beyond NSCLC, CRC, UC, RCC, BTC, and head and neck squamous cell carcinoma (HNSCC). • In addition to the multiregional studies conducted and sponsored by Summit, Akeso is...

    Company
    Summit Therapeutics Inc.
    Source
    SEC Form 8-K · Financial results
  6. Quarterly reportCompany-reportedNov 4, 2026

    Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

    “The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union,” said Mark A.

    Company
    Revolution Medicines, Inc.
    Source
    SEC Form 8-K · Financial results
  7. Quarterly reportCompany-reportedNov 3, 2026

    Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    External expenses include (i) program-specific expenses, which decreased by $6.7 million, primarily driven by a decrease in the vepdegestrant (ARV-471) program of $14.2 million, partially offset by increases in the ARV-027, ARV-6723, and ARV-393 programs of $4.6 million, $3.3 million, and $3.2 million...

    Company
    Arvinas, Inc.
    Source
    SEC Form 8-K · Financial results, Regulation FD disclosure
  8. Quarterly reportCompany-reportedNov 3, 2026

    IGNITING A TRANSFORMATIVE CHANGE in the fight for patients with cancer and neurodegenerative diseases

    PROTAC:, proteolysis targeting chimera a. vepdegestrant, bavdegalutamide, luxdegalutamide (JSB462), ARV-102, ARV-393, ARV-806, ARV-027, ARV-6723 Our experienced and talented team is advancing a new therapeutic modality for patients 4 History of FIRSTS with our novel Clinical trials in oncology Discovery Clinical...

    Company
    Arvinas, Inc.
    Source
    SEC Form 8-K · Financial results, Regulation FD disclosure
  9. Quarterly reportCompany-reportedNov 3, 2026

    AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

    Olpasiran (AMG 890) • Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. • The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV...

    Company
    Amgen
    Source
    SEC Form 8-K · Financial results
  10. Trial resultsCompany-reportedOct 29, 2026

    Novo to present new CagriSema and Wegovy® data at ObesityWeek® 2026, including data on treatment experience with Wegovy® pill in the real world

    Novo Nordisk today announced that new data from its obesity portfolio will be presented across 26 abstracts at ObesityWeek ® 2026, taking place November 14–17 in Washington, D.C., US.

  11. Quarterly reportCompany-reportedOct 29, 2026

    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

    “The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline.

    Source
    SEC Form 8-K · Financial results
  12. Quarterly reportCompany-reportedOct 29, 2026

    Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

    “Exelixis continued to execute across all of our key priorities in the third quarter, driving the cabozantinib franchise forward while preparing for zanzalintinib as our next potential franchise opportunity,” said Michael M.

    Company
    Exelixis, Inc.
    Source
    SEC Form 8-K · Financial results
  13. Quarterly reportCompany-reportedOct 29, 2026

    Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

    “Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.

    Source
    SEC Form 8-K · Financial results
  14. Trial resultsCompany-reportedOct 28, 2026

    Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

    Eli Lilly and Company (NYSE: LLY ), the maker of Mounjaro (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes.

  15. RegulatoryCompany-reportedOct 27, 2026

    New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application ("the application") for its trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱...

    Company
    Sichuan Kelun-Biotech
  16. Quarterly reportCompany-reportedOct 27, 2026

    CONDENSED FINANCIAL REPORT

    Selected innovative medicines projects awaiting regulatory decisions Completed submissions Product Indication US EU Japan News update Cosentyx Polymyalgia rheumatica Q1 2026 Q1 2026 Q1 2026 – Positive CHMP opinion – Efficacy supplement for IV regimen submitted to FDA Hidradenitis suppurativa, pediatrics aged 12+...

    Company
    Novartis
  17. Quarterly reportCompany-reportedOct 27, 2026

    FINANCIAL REPORT Q3 2026

    TQJ230 (pelacarsen) In the Phase III HORIZON trial, pelacarsen did not meet its primary endpoint of reducing the risk of cardiovascular events versus placebo in patients with elevated Lp(a) and established cardiovascular disease (CVD), despite reducing Lp(a) levels in this study population.

    Company
    Novartis
  18. Trial resultsCompany-reportedOct 25, 2026

    Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium

    Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase III HARMONi-GI1 trial (AK112-309).

    Company
    Akeso, Inc.
  19. Trial resultsCompany-reportedOct 25, 2026

    Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the prespecified final overall survival (OS) analysis results of the Phase III OptiTROP-Lung04 study of sacituzumab...

    Company
    Sichuan Kelun-Biotech
  20. Investor presentationCompany-reportedOct 25, 2026

    The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the Phase III OptiTROP-Lung06 study of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱...

    Company
    Sichuan Kelun-Biotech

How to read these disclosures

Every card is company-reported: it summarizes what a company said about its own drug. Most come from press releases filed with the SEC on Form 8-K (U.S. companies) or Form 6-K (foreign companies); companies must file material news, so these filings are a reliable record of what was announced and when. Others come from PR Newswire, which covers companies that issue news there without filing it, such as Eli Lilly and Akeso. When the same release appears in both, we show the SEC copy. Neither is independent verification. Topline results in particular are often reported before peer review.

Disclosure types are assigned automatically from the wording of each release and may occasionally be wrong. Quarterly reports are included when they mention a tracked drug, since they often contain pipeline updates. Each card links to the original document on SEC.gov or PR Newswire. For how we weigh company claims against peer-reviewed and regulatory evidence, see our editorial standards; for what a trial result means, read What Is a Primary Clinical Trial Endpoint?

Nothing on this page is investment advice.